Keele Research Repository

Article

Bundred, N, Porta, N, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Cramer, A, Hanby, A, Shaaban, AM, Rakha, EA, Armstrong, A, Cutress, RI, Dodwell, D, Emson, MA, Evans, A, Hartup, SM, Horgan, K, Miller, SE, McIntosh, SA, Morden, JP, Naik, J, Narayanan, S, Ooi, J, Skene, AI, Cameron, DA and Bliss, JM (2022) Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research, 28 (7). 1323 - 1334.

Cameron, D, Morden, JP, Canney, P, Velikova, G, Coleman, R, Bartlett, J, Agrawal, R, Banerji, J, Bertelli, G, Bloomfield, D, Brunt, AM, Earl, H, Ellis, P, Gaunt, C, Gillman, A, Hearfield, N, Laing, R, Murray, N, Couper, N, Stein, RC, Verrill, M, Wardley, A, Barrett-Lee, P and Bliss, JM (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). 929 - 945.

Brunt, AM, Wheatley, D, Yarnold, J, Somaiah, N, Kelly, S, Harnett, A, Coles, C, Goodman, A, Bahl, A, Churn, M, Zotova, R, Sydenham, M, Griffin, CL, Morden, JP and Bliss, JM (2016) Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120 (1). pp. 114-118.